Cambrex expands at two US sites

Cambrex has announced it is investing in a new facility in Minneapolis. It will operate as an extension of the flagship facility in Charles City, Iowa (pictured), which is simultaneously seeing further expansion.

The new site, near Minneapolis–St. Paul Airport, will specialise in analytical and chemical development for small molecule drug candidates and will cover 1,950 m2 R&D. This will double Cambrex’s analytical and chemical development footprint in the Midwest, according to CEO Thomas Loewald, while creating 46 jobs.

Meanwhile, the multi-phase, 835 m2 expansion and 1,950 m2 renovation project in Charles City will add a QC laboratory and administrative office space, bringing 40 new jobs. This follows a $50 million expansion, which was completed in Q1, and which, the firm said, established it as “the largest, most advanced API manufacturing site in the United States”.